

		Conditions:	Adult Diffuse Astrocytoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor; Adult Oligoastrocytoma
		Interventions:	Biological: tumor lysate-pulsed autologous dendritic cell vaccine; Other: laboratory biomarker analysis
447	Active, not recruiting	Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs	
		Conditions:	Cervical Cancer; Papillomavirus Infection
		Intervention:	Biological: GSK Bio's HPV vaccine 580299 (Cervarix TM)
448	Unknown †	Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer	
		Condition:	Breast Cancer
		Interventions:	Biological: incomplete Freund's adjuvant; Biological: sargramostim; Biological: telomerase: 540-548 peptide
449	Unknown †	Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia	
		Conditions:	Cervical Cancer; Precancerous Condition
		Intervention:	Biological: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
450	Completed	Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor	
		Conditions:	Brain and Central Nervous System Tumors; Gastrointestinal Stromal Tumor; Sarcoma
		Interventions:	Biological: sargramostim; Biological: telomerase: 540-548 peptide vaccine
451	Completed	Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant	
		Conditions:	Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonmalignant Neoplasm
		Interventions:	Biological: trivalent influenza vaccine; Other: immunoenzyme technique; Other: laboratory biomarker analysis
452	Recruiting	Autologous OC-DC Vaccine in Ovarian Cancer	
		Conditions:	Chemotherapy; Tumor; Ovarian Cancer
		Intervention:	Biological: OCDC
453	Completed	Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors	
		Condition:	Liver Neoplasms
		Interventions:	Drug: rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM; Drug: rF-CEA(6D)/TRICOM; Drug: Recombinant Fowlpox-
454	Completed	Health SMART (Stress Management and Relaxation Training)	
		Condition:	Breast Cancer
		Intervention:	Behavioral: Cognitive Behavioral Stress Management (CBSM)
455	Active, not recruiting	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	
		Condition:	Malignant Neoplasms of Brain
		Interventions:	Biological: PEP-3-KLH conjugate vaccine; Biological: sargramostim; Other: placebo
456	Completed	Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	
		Conditions:	Intraocular Melanoma; Malignant Conjunctival Neoplasm; Melanoma (Skin)
		Interventions:	Biological: MART-1:27-35 peptide vaccine; Biological: gp100:209-217(210M) peptide vaccine; Biological: incomplete Freund's adjuvant; Biological: sargramostim; Biological: tyrosinase peptide; Drug: agatolimod
457	Completed	Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery	
		Condition:	Lung Cancer, Non-Small Cell
		Interventions:	Biological: GSK 249553 vaccine; Biological: Placebo
458	Terminated	Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia	
	Has	Condition:	Leukemia
		Interventions:	Biological: bcr-abl peptide vaccine; Genetic: reverse transcriptase-polymerase chain reaction

459	Completed	Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma
		Condition: Prostatic Neoplasms Intervention: Biological: Transgenic Lymphocyte Immunization Vaccine (TLI)
460	Active, not recruiting Has	Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
		Condition: Prophylaxis for HPV Infections and Associated Cervical Neoplasia Interventions: Biological: Cervarix; Biological: Placebo control
461	Recruiting	A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
		Condition: Non-small Cell Lung Cancer Intervention: Biological: UV1 synthetic peptide vaccine and GM-CSF
462	Completed	Safety Study of BLP25 Liposome Vaccine in Non-Small Cell Lung Cancer Patients With Unresectable Stage III Disease
		Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms Intervention: Biological: BLP25 Liposome Vaccine
463	Active, not recruiting	Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
		Condition: Breast Cancer Interventions: Biological: sargramostim; Biological: therapeutic autologous dendritic cells; Biological: trastuzumab; Drug:
464	Recruiting	Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
		Condition: Cervical Cancer Intervention: Biological: HPV Vaccine (Gardasil)
465	Completed	Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response
		Condition: Psychological Stress Intervention: Behavioral: Cognitive Behavioral Stress Management (CBSM) group intervention
466	Completed	MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
		Condition: Castrate Resistant Prostate Cancer (CRPC) Interventions: Biological: BPX-101; Drug: AP1903
467	Completed	Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
		Conditions: Anal Cancer; Cervical Cancer; Esophageal Cancer; Head and Neck Cancer; Penile Cancer; Vulvar Cancer Interventions: Biological: human papillomavirus 16 E7 peptide; Biological: synthetic human papillomavirus 16 E6 peptide
468	Completed	Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer
		Condition: Lung Cancer Interventions: Biological: autologous tumor cell vaccine; Biological: therapeutic autologous dendritic cells; Procedure: conventional surgery
469	Recruiting	Open Label Study to Evaluate the Safety and Tolerability of GI-6301 (Whole Heat-Killed Recombinant Yeast Modified to Express Brachyury
		Condition: Solid Tumors Intervention: Biological: GI-6301
470	Completed	Vaccine Therapy in Treating Patients With Liver Cancer
		Condition: Liver Cancer Intervention: Biological: AFP gene hepatocellular carcinoma vaccine
471	Active, not recruiting Has	Vaccine Therapy and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Treating Patients With Prostate Cancer That Progressed After Surgery and/or Radiation Therapy
		Condition: Prostate Cancer Interventions: Biological: vaccinia; Biological: GM-CSF; Biological: fowlpox; Drug: bicalutamide; Drug: goserelin

472	Completed	Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
		Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
		Interventions: Biological: NY-ESO-1 peptide vaccine; Biological: incomplete Freund's adjuvant
473	Recruiting	Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation
		Condition: Chronic Lymphocytic Leukemia
		Intervention: Procedure: Leukemia cell harvest
474	Completed	Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
		Conditions: Colorectal Cancer; Neoplasm Metastasis
		Interventions: Biological: monoclonal antibody 11D10 anti-idiotype; Biological: monoclonal antibody 3H1 Alu Gel
475	Unknown †	Vaccine Therapy in Treating Patients With Head and Neck Cancer
		Condition: Head and Neck Cancer
		Interventions: Biological: mutant p53 peptide pulsed dendritic cell vaccine; Biological: tetanus toxoid helper peptide; Procedure: adjuvant therapy
476	Active, not recruiting	GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
		Condition: Brain and Central Nervous System Tumors
		Interventions: Biological: HSPPC-96; Procedure: conventional surgery
477	Unknown †	Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
		Conditions: Breast Cancer; Gastric Cancer; Lung Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol
		Intervention: Biological: MVF-HER-2(628-647)-CRL 1005 vaccine
478	Unknown †	Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
		Condition: Breast Cancer
		Intervention: Biological: recombinant vaccinia DF3/MUC1 vaccine
479	Completed	Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
		Condition: Breast Cancer
		Interventions: Biological: GM2-KLH vaccine; Biological: QS21
480	Completed	Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer
		Condition: Pancreatic Cancer
		Interventions: Biological: allogeneic tumor cell vaccine; Biological: recombinant interferon alfa; Biological: sargramostim; Drug:
481	Completed	Vaccine Therapy in Treating Patients With Breast Cancer
		Condition: Breast Cancer
		Intervention: Biological: MUC1-KLH vaccine/QS21
482	Withdrawn	Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
		Condition: Metastatic Solid Tumors
		Intervention: Biological: Tumor Cell Vaccine
483	Completed	HER-2 Protein Vaccine in Treating Women With Breast Cancer
		Condition: Breast Cancer
		Intervention: Biological: HER-2/neu peptide vaccine
484	Completed	Vaccine Therapy in Treating Patients With Advanced Cancer
		Condition: Unspecified Adult Solid Tumor, Protocol Specific
		Intervention: Biological: MVA-MUC1-IL2 vaccine
485	Recruiting	Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
		Condition: Lung Cancer
		Intervention: Biological: autologous dendritic cell-adenovirus CCL21 vaccine

486	Completed	Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer	
		Condition:	Prostate Cancer
		Intervention:	Biological: PSA RNA-pulsed dendritic cell vaccine
487	Unknown †	Chemotherapy, Vaccine Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Multiple Myeloma	
		Condition:	Multiple Myeloma and Plasma Cell Neoplasm
		Interventions:	Biological: autologous tumor cell vaccine; Drug: chemotherapy; Procedure: autologous hematopoietic stem cell
488	Completed	Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer	
		Condition:	Prostate Cancer
		Interventions:	Biological: recombinant viral vaccine therapy; Biological: sargramostim
489	Recruiting	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell	
		Conditions:	Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma;
		Interventions:	Biological: tetanus-CMV fusion peptide vaccine; Other: laboratory biomarker analysis
490	Completed	Melanoma Vaccine With Peptides and Leuprolide	
		Condition:	Melanoma
		Interventions:	Drug: Leuprolide; Biological: GP100: 209-217(210M) Peptide; Biological: MAGE-3 Peptide
491	Completed	Vaccine Therapy in Treating Patients With Metastatic Cancer	
		Conditions:	Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific
		Interventions:	Biological: aldesleukin; Biological: incomplete Freund's adjuvant; Biological: telomerase: 540-548 peptide vaccine
492	Completed	Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer	
		Condition:	Cervical Cancer
		Interventions:	Biological: human papillomavirus 16 E7 peptide; Procedure: in vitro-treated peripheral blood stem cell transplantation
493	Completed	A Study of V503 Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006 AM1)	
		Conditions:	Cervical Cancers; Vulvar Cancers; Vaginal Cancers; Genital Warts
		Interventions:	Biological: V503; Biological: Placebo to V503
494	Unknown †	Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Colorectal Cancer	
		Condition:	Colorectal Cancer
		Intervention:	Biological: HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine
495	Completed	Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary	
		Conditions:	Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
		Interventions:	Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; Biological: sargramostim

496	Active, not recruiting	A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
		Condition: Multiple Myeloma Intervention: Biological: ImMucin, hGM-CSF
497	Completed	Vaccine Therapy in Treating Patients With Multiple Myeloma
		Conditions: Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm Interventions: Drug: autologous tumor cell vaccine; Drug: keyhole limpet hemocyanin; Drug: melphalan; Drug: sargramostim
498	Active, not recruiting	Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells
		Condition: Chronic Lymphocytic Leukemia (CLL) Intervention: Biological: CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE
499	Completed	Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients
		Condition: Brain and Central Nervous System Tumors Interventions: Biological: aldesleukin; Biological: autologous tumor cell vaccine; Biological: filgrastim; Biological: sargramostim;
500	Unknown †	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
		Condition: Melanoma (Skin) Interventions: Biological: autologous dendritic cell-tumor fusion vaccine; Biological: gp100 antigen; Biological: therapeutic
501	Not yet recruiting	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
		Conditions: HPV Infections; Precancerous Disease of the Cervix; Cervical Cancer; HPV Related Diseases Intervention: Biological: Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)
502	Recruiting	Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses
		Condition: Unspecified Adult Solid Tumor, Protocol Specific Interventions: Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine; Biological: recombinant interferon alfa-2b; Biological: recombinant vaccinia-CEA(6D)-TRICOM vaccine; Biological: sargramostim
503	Terminated	Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
		Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nonmalignant Neoplasm; Virus Diseases Interventions: Other: cytology specimen collection procedure; Other: fluorescent antibody technique; Procedure: assessment of therapy complications
504	Completed Has	Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
		Conditions: Chronic Myeloid Leukemia; Minimal Residual Disease Intervention: Biological: Synthetic Tumor-Specific Breakpoint Peptide Vaccine
505	Recruiting	A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster
		Condition: Herpes Zoster Interventions: Biological: V212; Biological: Placebo
506	Unknown †	Acceptability and Feasibility of Human Papilloma Virus Vaccine
		Condition: Cervical Cancer Intervention: Behavioral: Health education
507	Recruiting	Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
		Conditions: Neuroblastoma; Ewings Sarcoma; Osteogenic Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma

		Intervention:	Biological: Autologous dendritic cell vaccine with adjuvant
508	Completed	A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy	
		Condition:	Prostatic Neoplasms
		Interventions:	Drug: Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM); Drug: Recombinant Fowlpox-
509	Completed	Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer	
		Conditions:	Breast Cancer; Colorectal Cancer; Gallbladder Cancer; Gastric Cancer; Head and Neck Cancer; Liver Cancer; Ovarian Cancer; Pancreatic Cancer; Testicular Germ Cell Tumor
		Intervention:	Biological: TRICOM-CEA(6D)
510	Completed	Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer	
		Condition:	Nasopharyngeal Neoplasms
		Intervention:	Drug: EBV-LMP-2
511	Recruiting	Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination	
		Condition:	Chronic Lymphocytic Leukemia
		Interventions:	Biological: GM-K562 vaccine; Procedure: stem cell transplantation
512	Completed	Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer	
		Conditions:	Lung Neoplasm; Carcinoma, Bronchogenic
		Intervention:	Biological: Lucanix
513	Unknown †	Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients	
		Condition:	Prostate Cancer
		Intervention:	Biological: PEP-223/CoVaccine HT
514	Completed	Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer	
		Conditions:	Head and Neck Cancer; Metastatic Cancer
		Intervention:	Biological: recombinant fowlpox-TRICOM vaccine
515	Unknown †	Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast	
		Condition:	Breast Cancer
		Interventions:	Biological: therapeutic autologous dendritic cells; Procedure: conventional surgery; Procedure: neoadjuvant
516	Completed	Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells	
		Condition:	Metastatic Melanoma
		Interventions:	Biological: Autologous tumor cells plus dendritic cells; Drug: GM-CSF
517	Completed	A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix™ Vaccine in	
	Has	Conditions:	Human Papillomavirus (HPV) Infection; Associated Cervical Neoplasia; Papillomavirus Vaccines
		Interventions:	Biological: HPV-16/18 VLP/AS04 vaccine (Cervarix™); Biological: Placebo
518	Completed	Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study	
	Has	Condition:	Human Papillomavirus Infection
		Interventions:	Procedure: Liquid-based cytology (LBC) sampling; Procedure: Blood sampling
519	Recruiting	Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer	
		Condition:	Bile Duct Cancer
		Interventions:	Biological: Peptide vaccine for URLC10; Drug: Gemcitabine

520	Active, not recruiting	Vaccine Therapy in Treating Patients With Malignant Glioma
		Condition: Brain and Central Nervous System Tumors
		Intervention: Biological: glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
521	Recruiting	Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
		Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor
		Interventions: Drug: Montanide ISA-51/survivin peptide vaccine; Biological: sargramostim; Other: flow cytometry; Other: laboratory biomarker analysis; Other: immunoenzyme technique
522	Completed Has	Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
		Conditions: Hepatitis B; Cervical Intraepithelial Neoplasia; Human Papillomavirus Infection
		Interventions: Biological: Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™); Biological: Enderix
523	Completed	Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
		Condition: Leukemia
		Interventions: Biological: QS21; Biological: bcr-abl peptide vaccine
524	Active, not recruiting Has	Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015 AM5; EXT1; EXT2(AM1))
		Conditions: Cervical Cancer; Genital Warts
		Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Biological: Matching Placebo
525	Terminated	Docetaxel in Combination With GVAX® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
		Condition: Prostate Cancer
		Interventions: Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine; Drug: Chemotherapy (docetaxel and prednisone)
526	Active, not recruiting	Radiation Therapy, Tadalafil, Sargramostim, Gemcitabine, and Telomerase Vaccine (GV1001) in Patients With Pancreatic Cancer
		Condition: Locally Advanced Pancreatic Adenocarcinoma
		Intervention: Biological: tadalafil and vaccination
527	Recruiting	An Intervention Study To Improve HPV Immunization in Haitian and African American Girls
		Condition: Cervical Cancer
		Intervention: Behavioral: BNI-brief Negotiated Interview
528	Active, not recruiting	Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy
		Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
		Interventions: Biological: Lucanix™; Other: Placebo Comparator
529	Completed	A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies
		Conditions: Colorectal Cancer; Breast Cancer; Lung Cancer; Pancreatic Cancer; Colon Cancer
		Intervention: Biological: AVX701
530	Completed Has	Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
		Conditions: Human Papillomavirus (HPV) Infection; Associated Cervical Neoplasia; Papillomavirus Vaccines
		Interventions: Biological: Placebo; Biological: HPV-16/18 L1 VLP AS04 (Cervarix™)
531	Recruiting	Vaccine Therapy With or Without Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

		Conditions:	Recurrent Melanoma; Stage IV Melanoma
		Interventions:	Biological: NA17.A2 peptide vaccine; Biological: recombinant MAGE-3.1 antigen; Biological: recombinant interleukin-12; Biological: MART-1 antigen; Other: laboratory biomarker analysis
532	Unknown †	Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma	
		Conditions:	Neuroblastoma; Sarcoma
		Interventions:	Biological: aldesleukin; Biological: autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine; Biological: therapeutic autologous lymphocytes
533	Recruiting	Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer	
		Condition:	HPV-16 +ve Oropharyngeal Carcinoma
		Intervention:	Biological: ADXS11-001
534	Completed	Safety Study of Multiple Peptide Vaccine to Esophageal Cancer	
		Condition:	Esophageal Cancer
		Intervention:	Biological: LY6K, VEGFR1, VEGFR2
535	Recruiting	A Vaccine Trial for Patients With Stage III B, IV, or Recurrent Non-Small Cell Lung Cancer	
		Condition:	Non-Small Cell Lung Cancer (NSCLC)
		Intervention:	Biological: autologous dendritic cell adenovirus CCL21 vaccine
536	Unknown †	Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma	
		Condition:	Cutaneous Melanoma
		Intervention:	Biological: autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
537	Completed	Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors	
		Condition:	Glioblastoma
		Interventions:	Biological: Dendritic Cell Immunotherapy; Biological: Dendritic Cell Vaccine
538	Recruiting	Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery	
		Conditions:	Recurrent Melanoma; Stage IIA Melanoma; Stage IIB Melanoma; Stage IIC Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
		Interventions:	Drug: Montanide ISA 51 VG; Biological: MART-1 antigen; Other: laboratory biomarker analysis; Biological: Gag:267-274 peptide vaccine; Drug: resiquimod
539	Active, not recruiting	Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-	
		Conditions:	HER2-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
		Interventions:	Drug: ex vivo-expanded HER2-specific T cells; Drug: cyclophosphamide; Biological: denileukin diftitox; Other: flow cytometry; Other: immunoenzyme technique
540	Recruiting	DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma	
		Condition:	Renal Cell Carcinoma
		Interventions:	Biological: DC-CIK; Drug: IL-2/IFN-α
541	Active, not recruiting	Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer	
		Conditions:	Colorectal Cancer; Metastatic Cancer
		Interventions:	Biological: falimarev; Biological: inalimarev; Biological: sargramostim; Biological: therapeutic autologous
542	Active, not recruiting	Study of the BiovaxId Tumor Derived Idiotypic Vaccine in Patients With Follicular Lymphoma	
		Condition:	Non-Hodgkins Lymphoma

		Interventions:	Biological: FNHLId1; Biological: KLH + GM-CSF
543	Terminated	Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer	
		Conditions:	Colorectal Cancer; Colon Cancer; Rectal Cancer
		Intervention:	Biological: VEGFR1 and VEGFR2
544	Terminated	Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer	
		Conditions:	Colorectal Cancer; Colon Cancer; Rectal Cancer
		Intervention:	Biological: RNF43, TOMM34, VEGFR1 and VEGFR2
545	Recruiting	Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?	
		Conditions:	Cervical Cancer; Hpv; Warts
		Intervention:	Biological: Quadrivalent HPV for types 6, 11, 16 and 18
546	Completed	Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients	
		Condition:	Melanoma Stage III or IV
		Intervention:	Biological: autologous dendritic cell vaccine
547	Terminated	Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia	
		Condition:	Leukemia
		Interventions:	Drug: autologous tumor cell vaccine; Drug: therapeutic autologous dendritic cells; Procedure: tumor cell-derivative vaccine therapy
548	Terminated	Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma	
	Has	Conditions:	Melanoma; Cancer
		Interventions:	Biological: ALVAC(2) Melanoma multi-antigen therapeutic vaccine; Biological: Intron A, Interferon alpha -2b
549	Terminated	Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer	
		Condition:	Breast Cancer
		Intervention:	Biological: VEGFR1 and VEGFR2
550	Terminated	Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma	
	Has	Condition:	Stage IV Melanoma
		Interventions:	Biological: aldesleukin; Biological: allogeneic large multivalent immunogen vaccine
551	Recruiting	WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation	
		Condition:	Multiple Myeloma
		Interventions:	Biological: WT1 Analog Peptide Vaccine; Biological: Sargramostim (GM-CSF)
552	Completed	Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines	
		Conditions:	B Cell Lymphoma; Follicular Lymphoma; Lymphoma
		Interventions:	Drug: Id-KLH Vaccine; Drug: GM-CSF
553	Recruiting	Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy	
		Conditions:	Cancer; Influenza Viral Infections
		Interventions:	Biological: Standard Trivalent Influenza Vaccine; Biological: High-Dose Influenza Vaccine
554	Completed	Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)	

	Has	Conditions:	Human Papilloma Virus; Cervical Cancer; Vulvar Cancer; Vaginal Cancer; Genital Warts
		Interventions:	Biological: Octavalent HPV with 15 mcg IMX / AAHS; Biological: Octavalent HPV with 30 mcg IMX / AAHS;
555	Completed	Vaccine Treatment for Advanced Malignant Melanoma	
		Condition:	Malignant Melanoma
		Intervention:	Biological: HyperAcute-Melanoma Vaccine
556	Completed	Vaccine Therapy in Treating Patients With Advanced Melanoma	
		Conditions:	Intraocular Melanoma; Malignant Conjunctival Neoplasm; Melanoma (Skin)
		Interventions:	Biological: incomplete Freund's adjuvant; Biological: multi-epitope melanoma peptide vaccine; Biological: tetanus toxoid helper peptide; Procedure: biopsy
557	Unknown †	A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine	
		Condition:	Melanoma
		Interventions:	Biological: HyperAcute vaccine; Drug: Pegylated Interferon-Alpha 2b
558	Completed	A Study of V934/V935 Vaccine in Cancer Patients With Selected Solid Tumors (V934-002 AM 4)	
		Conditions:	Non-Small Cell Lung Carcinoma; Breast Cancer; Melanoma; Upper GI Tract Carcinoma; Colon Carcinoma; Renal Cell Carcinoma; Bladder Carcinoma; Prostate Cancer
		Interventions:	Biological: V935; Biological: V934
559	Recruiting	Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in	
		Condition:	Melanoma
		Intervention:	Biological: Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
560	Completed	Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women	
	Has	Conditions:	Cervical Cancer; Papillomavirus Infection
		Interventions:	Biological: Placebo; Biological: HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)
561	Active, not recruiting	Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been	
		Condition:	Malignant Neoplasms of Brain
		Interventions:	Biological: PEP-3-KLH conjugate vaccine; Biological: daclizumab; Drug: temozolomide; Other: placebo;
562	Completed	Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma	
		Condition:	Brain and Central Nervous System Tumors
		Intervention:	Biological: therapeutic autologous dendritic cells
563	Completed	Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma	
	Has	Conditions:	Melanoma; Skin Cancer
		Interventions:	Drug: MART-1: 26-35(27L) Peptide; Drug: Montanide ISA 51 VG; Drug: gp100:154-162 Peptide; Procedure: Radiation; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide; Genetic: Anti-gp 100:154 TCR
564	Unknown †	Rituximab, Autologous Vaccine Therapy, and Sargramostim in Treating Patients With Recurrent or Refractory Follicular B-Cell Lymphoma	
		Condition:	Lymphoma
		Interventions:	Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine; Biological: rituximab; Biological: sargramostim
565	Recruiting	Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be	
		Conditions:	Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
		Interventions:	Biological: HSPPC-96; Biological: bevacizumab